AIDS Clinical Trials Group (ACTG) / National Institute of Allergy and Infectious Diseases (NIAID): HIV Cure Study* May 18, 2023This Phase 1 randomized “HIV Cure Study” is evaluating whether ImmunityBio’s investigational agent N-803 along or together with broadly neutralizing antibodies can control HIV following antiretroviral therapy.
